NOTV INOTIV INC

Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences

Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences

WEST LAFAYETTE, Ind., May 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the upcoming 21st Annual Craig Hallum Institutional Investor Conference and Jefferies Global Healthcare Conference.

Conference Details

Event: 21st Annual Craig Hallum Institutional Investor Conference

Location: Minneapolis, MN

Date: May 29, 2024

Event format: 1-on-1 institutional investor meetings only

Event: Jefferies Global Healthcare Conference

Location: New York, NY

Date: June 4-6, 2024

Presentation Time: 10:30 AM Eastern Time on June 6th, 2024

Event Format: Presentations and 1-on-1 meetings

To schedule a meeting at the conferences with Inotiv management or for more conference information please contact your institutional sales rep at Craig Hallum and/or Jefferies.

About the Company

Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: .

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact included in this release, are forward-looking statements, including, but not limited to, statements about the anticipated timing of the filing of the Company’s second fiscal quarter Form 10-Q and issuance of financial results for such quarter. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “outlook,” “will,” “should,” “can have,” “likely,” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. All forward-looking statements are subject to significant risks, uncertainties and changes in circumstances that could cause actual results and outcomes to differ materially from the forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including, without limitation, the Company’s inability to file its second quarter 2024 Form 10-Q on a timely basis; the outcome of the completion of the preparation of the Company’s financial statements; the inability to reach a resolution with the DOJ or the impact of unfavorable terms of any such resolution; the impact of this announcement on the Company’s common stock, its relationships with employees, customers and suppliers; and those that are described in the Company’s most recent Annual Report on Form 10-K and in other documents that the Company files or furnishes with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except to the extent required by law, the Company does not undertake, and expressly disclaims, any duty or obligation to update publicly any forward-looking statement after the date of this announcement, whether as a result of new information, future events, changes in assumptions or otherwise.

Company ContactInvestor Relations
Inotiv, Inc.LifeSci Advisors
Beth A. Taylor, Chief Financial OfficerBob Yedid
(765) 497-8381(516) 428-8577


EN
23/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INOTIV INC

 PRESS RELEASE

Inotiv, Inc. to Report Fiscal 2025 Third Quarter Financial Results and...

Inotiv, Inc. to Report Fiscal 2025 Third Quarter Financial Results and Host Conference Call on Wednesday, August 6, 2025 WEST LAFAYETTE, Ind., July 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 third quarter ended June 30, 2025, on Wednesday, August 6, 2025, after the close of the stock market. Th...

 PRESS RELEASE

Inotiv, Inc. to Present at Jefferies Global Healthcare Conference 2025

Inotiv, Inc. to Present at Jefferies Global Healthcare Conference 2025 WEST LAFAYETTE, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer will present at the upcoming Jefferies Global Healthcare Conference in New York. The live presentation will take place on Wednesday, June 4 at 3:45 p.m. E...

 PRESS RELEASE

Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Pr...

Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update —  Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million—  Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million—  Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial result...

 PRESS RELEASE

Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results an...

Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results and Host Conference Call on Wednesday, May 7, 2025 WEST LAFAYETTE, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 second quarter ended March 31, 2025, on Wednesday, May 7, 2025, after the close of the stock market. The ...

 PRESS RELEASE

Inotiv Reports First Quarter Financial Results for Fiscal 2025 and Pro...

Inotiv Reports First Quarter Financial Results for Fiscal 2025 and Provides Business Update Enhanced liquidity by $27.5 million through the issuance of 6.9 million common sharesFirst quarter fiscal 2025 revenue declined 11.5% to $119.9 millionConference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch